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randomised controlled trials
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Summary
Background About 47% of preschool children worldwide are anaemic. Daily oral iron supplementation is a commonly 
recommended intervention for treatment and prevention of anaemia, but the eﬃ  cacy and safety of iron 
supplementation programmes is debated. Thus, we systematically reviewed the evidence for beneﬁ t and safety of 
daily iron supplementation in children aged 4–23 months.
Methods We searched Scopus and Medline, from inception to Feb 5, 2013, WHO databases, theses repositories, grey 
literature, and references. Randomised controlled trials that assigned children 4–23 months of age to daily oral iron 
supplementation versus control were eligible. We calculated mean diﬀ erence (MD) or standard MD (SMD) for 
continuous variables, risk ratios for dichotomous data, and rate ratios for rates. We quantiﬁ ed heterogeneity with the 
I2 test and synthesised all data with a random-eﬀ ects model. This review is registered with the International 
Prospective Register of Systematic Reviews, number CRD42011001208.
Findings Of 9533 citations identiﬁ ed by the search strategy, 49 articles from 35 studies were eligible; these trials 
included 42 306 children. Only nine studies were judged to be at low risk of bias. In children receiving iron 
supplements, the risk ratio for anaemia was 0·61 (95% CI 0·50–0·74; 17 studies, n=4825), for iron deﬁ ciency was 
0·30 (0·15–0·60; nine studies, n=2464), and for iron deﬁ ciency anaemia was 0·14 (0·10–0·22; six studies, n=2145). 
We identiﬁ ed no evidence of diﬀ erence in mental (MD 1·65, 95% CI –0·63 to 3·94; six studies, n=1093) or 
psychomotor development (1·05, –1·36 to 3·46; six studies, n=1086). We noted no signiﬁ cant diﬀ erences in ﬁ nal 
length or length-for-age, or ﬁ nal weight or weight-for-age. Children randomised to iron had slightly lesser length 
(SMD –0·83, –1·53 to –0·12; eight studies, n=868) and weight gain (–1·12, –1·19 to –0·33) over the course of the 
studies. Vomiting (risk ratio 1·38, 95% CI 1·10–1·73) and fever (1·16, 1·02–1·31) were more prevalent in children 
receiving iron.
Interpretation In children aged 4–23 months, daily iron supplementation eﬀ ectively reduces anaemia. However, the 
adverse eﬀ ect proﬁ le of iron supplements and eﬀ ects on development and growth are uncertain. Adequately powered 
trials are needed to establish the non-haematological beneﬁ ts and risks from iron supplementation in this group.
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College of Physicans); Overseas Research Experience Scholarship, University of Melbourne.
Introduction
More than 1·6 billion people worldwide are anaemic and 
the prevalence is highest (47·4%) in preschool children,1 
especially those aged 4–23 months. Iron deﬁ ciency is 
thought to be the commonest cause of anaemia worldwide.1 
Complex factors interact to cause iron deﬁ ciency in children 
aged 4–23 months: inadequate iron stores attributable to 
low birthweight and prematurity, increased requirements 
during rapid growth and erythropoiesis, inadequate iron 
content and availability from complementary foods 
(introduced at 4–6 months of age),2 and blood loss due to 
parasitic infection.3 Beyond anaemia, iron deﬁ ciency in 
early childhood has been associated with many adverse 
eﬀ ects, especially potentially irreversible cognitive deﬁ cits 
associated with impairment to CNS structural and 
metabolic development.4 Iron supplementation 
programmes are premised on the assumption that iron will 
beneﬁ t anaemia and also non-haematological outcomes.5
The importance of prevention of undernutrition 
during gestation and the ﬁ rst 2 years (ﬁ rst 1000 days) of 
life for optimum development has been re-emphasised.6 
Daily iron supplementation is a widely recommended 
strategy for anaemia control (including by WHO7) 
although these recommendations are not based on a 
systematic review of this speciﬁ c intervention. In the 
past decade, randomised controlled trials and previous 
systematic reviews have reported uncertain beneﬁ ts and 
safety of iron supplementation in young children.8–10 
Understanding of the risks and beneﬁ ts of daily iron 
supplementation is crucial to develop an appropriate 
evidence base for anaemia control policy. This 
systematic review and meta-analysis aims to 
comprehensively assess the eﬀ ect of daily iron 
supplementation in children aged 4–23 months on 
important haematological and non-haematological 
outcomes and adverse eﬀ ects.
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Methods
Search strategy and selection criteria
We searched Scopus (comprises Embase and Medline) 
and Medline (separately; from inception to Feb 5, 2013), 
Cochrane Controlled Clinical Trials Register, Proquest 
Digital Theses, Australian Digital Theses Database, and 
OpenSigle (in March, 2012). We also searched WHO 
regional databases (AIM, AFROMED, LILACS, IMSEAR, 
WPRIM, and IMEMR; from inception to April 4, 2012). 
We reviewed references of identiﬁ ed articles and previous 
systematic reviews. We applied no language restrictions. 
We searched the WHO International Clinical Trials 
Registry Platform in March, 2013, to identify ongoing or 
unpublished potentially eligible trials. The Scopus search 
strategy is presented in appendix p 2.
Randomised controlled trials assigning community or 
outpatient, otherwise well children aged 4–23 months to 
daily oral iron supplements versus control were eligible. 
Studies that combined iron supplements with a second 
intervention were eligible when the co-intervention was 
applied identically (without iron) in the control group 
(studies comparing multiple micronutrients containing 
iron with control were thus ineligible). When a study did 
not speciﬁ cally recruit children aged 4–23 months, it 
remained eligible when the mean or median age was 
within 4–23 months, when at least 75% of participants 
were within the designated age range, or when most of 
the study’s designated recruitment age range overlapped 
4–23 months.
Data extraction and management
Two authors independently screened the titles and 
abstracts identiﬁ ed by the search and excluded those for 
which title and abstract indicated clear ineligibility. Full-
text studies were screened for eligibility against the 
inclusion criteria by two authors independently. Data 
were extracted in duplicate by diﬀ erent authors 
independently. One author then entered data into Review 
Manager software (RevMan, version 5.1) and a second 
author checked entries for accuracy. Discrepancies were 
resolved through discussion.
Assessment of risk of bias in included studies
Two authors independently assessed risk of bias using the 
Cochrane instrument,11 according to established criteria 
(appendix pp 3–4). Discrepancies were resolved through 
discussion. We did a sensitivity analysis including only 
studies judged at low overall risk of bias (appendix 
pp 18–20).12 We used funnel plots to assess potential 
publication bias for outcomes with more than ten trials.
Outcomes
We selected outcomes to inform guidelines for anaemia 
control13 by assessing potential beneﬁ ts and risks relevant 
to implementation of public health anaemia control 
programmes in low-income and middle-income 
countries. Primary outcomes were: haemoglobin (g/L), 
anaemia (deﬁ ned by study investigators), iron status 
(iron indices, including ferritin), iron deﬁ ciency (deﬁ ned 
by study investigators), iron deﬁ ciency anaemia (IDA, 
deﬁ ned by study investigators), cognitive and 
psychomotor development, physical growth, and safety 
(ie, gastrointestinal eﬀ ects, infections such as malaria, 
mortality). Secondary outcomes included eﬀ ects of iron 
on other micronutrients (eg, zinc, vitamin A).
Synthesis of results
We did meta-analysis for outcomes reported by at least 
two trials. For continuous data measured on the same 
scale, mean diﬀ erence (MD) was estimated. Data using 
diﬀ erent scales were combined with standardised MD 
(SMD).14 When, for particular outcomes, some studies 
reported endpoint data only and others reported change 
from baseline only, these were combined using MD when 
the same scale had been used.14 When studies reported 
both endpoint and change from baseline data for the 
same outcome, endpoint data were used. For dichotomous 
data, we calculated risk ratios. For rates, we calculated 
rate ratios. We extracted 2×2 factorial studies as two 
separate experiments (iron supplementation vs control, 
iron supplementation plus co-intervention vs co-
intervention alone); these data were entered into the 
meta-analysis separately.
We quantiﬁ ed heterogeneity with the I² test; we 
deemed substantial heterogeneity to exist when I² 
exceeded 50%. For each outcome, subgroup analysis was 
done to explain potential methodological or clinical 
heterogeneity.14 Subgroups included baseline anaemia 
and iron status, dose and duration of supplementation, 
present breastfed status, and malaria endemicity of the 
study setting (appendix p 1). We compared eﬀ ect sizes in 
subgroups when at least three studies were included per 
stratum, using the adapted χ² p and I² statistics of 
Borenstein.15 We drew forest plots to present the eﬀ ect 
size and relative weighting for each study and the overall 
calculated eﬀ ect size. In view of potential heterogeneity, 
all data were synthesised with a random-eﬀ ects model, 
with calculation of the τ² value.14 This review is registered 
at the International Prospective Register of Systematic 
Reviews (PROSPERO), number CRD42011001208.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all data in the study and had ﬁ nal responsibility 
for the decision to submit for publication.
Results
The search identiﬁ ed 9533 papers. We did not identify 
any ongoing or unpublished studies through WHO 
ICTRP. The outcome of papers that underwent full-text 
review is presented in appendix pp 6–12. After screening, 
49 papers relating to 35 trials were eligible, of which 
See Online for appendix
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33 contained data that could be extracted (ﬁ gure 1). 
These 33 trials included 42 015 children, with 21 175 
randomised to iron supplementation and 21 089 to 
control. Excluding the large studies by Sazawal and 
colleagues10 and Tielsch and colleagues16 (32 976 children; 
appendix p 21), which used cluster randomisation, 9039 
children were included, 4690 randomised to iron 
supplements and 4350 to control.
Appendix pp 13–17 show characteristics of included 
studies. Iron was generally provided as ferrous salts, 
including ferrous sulfate in 22 studies (six studies did 
not specify preparation). Only one study reported quality 
control testing of supplements.17 Nine studies were 
judged at low overall risk of bias (appendix pp 18–20) for 
sensitivity analysis.
Findings for meta-analysis of primary outcomes are 
summarised in the table. Appendix pp 28–41 detail all 
results including, for outcomes containing six or more 
studies, subgroup analysis.
Iron supplementation increased haemoglobin and 
ferritin and reduced the prevalence of anaemia, iron 
deﬁ ciency, and IDA (table, appendix pp 22–24). 
We identiﬁ ed no evidence of publication bias for eﬀ ects 
of iron on haemoglobin, ferritin, and anaemia (appendix 
pp 25–26). As shown in appendix pp 27–31, these 
Figure 1: Study ﬂ ow diagram
RCT=randomised controlled trial.
9004 studies identiﬁed from initial 
search of Scopus and Medline
524 studies identiﬁed from WHO 
regional databases 
5 studies identiﬁed from 
theses repositories
9533 titles and abstracts screened
9459 ineligible on basis of title 
and abstract
94 full-text references accessed
16 unable to locate full text 
28 excluded
9 not RCT 
6 intervention group not 
daily iron 
6 incorrect age 
5 foodlets containing 
macronutrients not present 
in control group 
1 inclusion criteria speciﬁed 
severe anaemia 
1 control group included iron
35 eligible studies (49 references)
2 unable to extract data
33 studies included
Number 
of trials
Number of 
participants
Measure of diﬀ erence 
(95% CI)
p value 
for eﬀ ect
I2
Haematology
Haemoglobin (g/L) 26 5479 MD 7·22 (4·87 to 9·57) <0·0001 94%
Mean cell volume (fL) 10 1434 MD 2·81 (1·20 to 4·42) 0·001 88%
Anaemia 17 4825 Risk ratio 0·61 (0·50 to 0·74) <0·0001 86%
Iron indices
Ferritin (ng/mL) 23 4236 MD 21·42 (17·25 to 25·58) <0·0001 98%
Transferrin saturation (%) 7 774 MD 6·00 (2·65 to 9·35) 0·0004 81%
Transferrin receptor 3 837 SMD –0·99 (–1·60 to –0·39) 0·001 94%
Serum iron (mcg/dL) 4 210 MD 3·56 (–1·79 to 8·91) 0·19 79%
Erythrocyte protoporphyrin 4 747 SMD –0·32 (–0·61 to –0·03) 0·03 72%
Iron deﬁ ciency (ferritin) 9 2464 Risk ratio 0·30 (0·15 to 0·60) 0·0006 94%
Iron deﬁ ciency anaemia 6 2145 Risk ratio 0·14 (0·10 to 0·22) <0·0001 0%
Other micronutrients
Serum zinc (μmol/L) 6 1988 MD –0·70 (–1·37 to –0·03) 0·04 85%
Retinol (μmol/L) 3 429 MD –0·07 (–0·15 to 0·01) 0·02 68%
Development
Bayley’s mental development 
index (score)
6 1093 MD 1·65 (–0·63 to 3·94) 0·16 66%
Bayley’s psychomotor 
development index (score)
6 1086 MD 1·05 (–1·36 to 3·46) 0·39 67%
Growth
Weight (kg) 8 2702 MD –0·02 (–0·09 to 0·05) 0·56 25%
Weight for age (Z-score) 8 3237 MD –0·02 (–0·08 to 0·03) 0·43 0%
Change in weight 8 868 SMD –1·12 (–1·91 to –0·33) 0·0005 96%
Length (cm) 7 2470 MD –0·13 (–0·33 to 0·07) 0·20 0%
Length for age (Z-score) 8 3237 MD 0·01 (–0·04 to 0·06) 0·71 4%
Change in length 8 868 SMD –0·83 (–1·53 to –0·12) 0·02 95%
Weight for length (Z-score) 5 2763 MD 0·03 (–0·06 to 0·12) 0·50 46%
Stunting 3 1504 Risk ratio 1·10 (0·92 to 1·32) 0·29 0%
Wasting 3 1504 Risk ratio 1·03 (0·65 to 1·64) 0·89 0%
Adverse eﬀ ects
Vomiting 3 1020 Risk ratio 1·38 (1·10 to 1·73) 0·006 1%
Diarrhoea (prevalence) 6 1697 Risk ratio 1·03 (0·86 to 1·23) 0·78 0%
Diarrhoea (incidence) 5 ·· Rate ratio 0·98 (0·88 to 1·09) 0·69 0%
Constipation 2 570 Risk ratio 0·54 (0·05 to 5·83) 0·49 77%
Any side-eﬀ ects 3 912 Risk ratio 1·10 (0·98 to 1·25) 0·12 0%
Fever (prevalence) 4 1318 Risk ratio 1·16 (1·02 to 1·31) 0·02 0%
Fever (incidence) 2 ·· Rate ratio 1·08 (0·79 to 1·47) 0·63 0%
Acute respiratory infection 2 944 Risk ratio 1·04 (0·92 to 1·19) 0·51 0%
Lower RTI (incidence) 3 ·· Rate ratio 1·00 (0·89 to 1·12) 0·96 0%
Clinical malaria 3 ·· Rate ratio 0·91 (0·71 to 1·17) 0·47 53%
All malaria episodes 2 ·· Rate ratio 0·81 (0·64 to 1·03) 0·08 0%
Malaria parasitaemia 2 ·· Rate ratio 0·96 (0·81 to 1·15) 0·68 0%
Outpatient attendances 2 ·· Rate ratio 1·00 (0·88 to 1·15) 0·97 0%
Mortality 2 ·· Rate ratio 1·10 (0·91 to 1·34) 0·33 0%
MD=mean diﬀ erence. SMD=standard MD. RTI=respiratory tract infection. 
Table: Summary of ﬁ ndings
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improvements tended to be greatest in children with 
baseline anaemia or iron deﬁ ciency, although most 
studies did not stratify inclusion by these disorders. 
Nevertheless, we also noted signiﬁ cant beneﬁ ts in 
children with unknown baseline anaemia and iron 
status. Longer duration (>3 months vs <1 month) of 
supplementation seemed to have a greater eﬀ ect on 
ferritin and transferrin saturation but not on 
haematological indices. When only trials at low risk of 
bias were included (haemoglobin, seven trials; ferritin, 
ﬁ ve trials; anaemia, seven trials; iron deﬁ ciency, four 
trials; IDA, three trials), signiﬁ cant improvements in 
these outcomes were still noted (data not shown).
Cognitive development was reported using Bayley’s 
mental development index in six studies.18–23 We identiﬁ ed 
no signiﬁ cant diﬀ erence in Bayley’s mental development 
index in children receiving iron compared with control 
(ﬁ gure 2A). When only studies at low risk of bias (two 
trials21,23) were included, MD was 2·05 (95% CI –1·46 to 
5·55; p=0·25). Subgroup analysis did not show evidence 
of beneﬁ t on mental development index from iron 
supplementation in children who were anaemic (MD 
4·46, 95% CI –9·32 to 18·24; p=0·53); however, there was 
evidence of a beneﬁ cial eﬀ ect in children with iron 
deﬁ ciency at baseline (MD 5·90, 95% CI 1·81 to 10·00; 
p=0·005; appendix p27). A further two studies measured 
cognitive development by diﬀ erent methods. Siegel24 and 
Surkan and colleagues25 reported no diﬀ erence from iron 
supplementation in Fagan intelligence scale, or attainment 
of cognitive or motor milestones in Nepalese children, 
respectively. Pongcharoen and colleagues26 could not 
identify any evidence of long-term cognitive improvement 
(measured by the Wechsler Intelligence Scale for Children, 
Raven’s Colored Progressive Matrices, or school 
performance) in Indonesian children randomised to iron 
with zinc versus zinc alone at 4–6 months of age.
We identiﬁ ed no signiﬁ cant diﬀ erence in Bayley’s 
Psychomotor Development Index in children receiving 
iron supplements (ﬁ gure 2B).18–23 When only studies at 
low risk of bias (two trials21,23) were included, MD was 
2·21 (95% CI –2·29 to 6·71; p=0·34). Aukett and 
colleagues27 noted no beneﬁ t in psychomotor development 
measured by the Denver development scale in children 
with anaemia randomised to iron versus control (MD 
0·80, 95% CI –0·18 to 1·78; p=0·11).
Physical growth was reported in diﬀ erent studies as 
length and weight at the end of the intervention; change 
in length and weight over the duration of the study; and 
as Z scores for weight-for-age, length-for-age, or weight-
for-length, at study endpoint. No studies reported 
absolute, normalised, or change in length or weight in 
children who were anaemic or iron deﬁ cient. We 
identiﬁ ed no diﬀ erences between children randomised 
to iron or control in ﬁ nal length, length-for-age Z score, 
ﬁ nal weight, weight-for-age Z score, or weight-for-
length Z score (ﬁ gures 3, 4), with much the same 
results when only studies at low risk of bias were 
included (data not shown).
Figure 2: Forest plots for eﬀ ect of daily iron supplementation on development
(A) Bayley’s mental development index. (B) Bayley’s psychomotor development index. *Inverse variance, random eﬀ ects. 
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When growth was reported as change from baseline, 
children who received iron supplementation had 
signiﬁ cantly reduced length gain (ﬁ gure 3C) and weight 
gain (ﬁ gure 4C) compared with control. Subgroup 
analysis showed that children receiving more than 
3 months of iron supplementation had reduced weight 
gain (SMD –2·39, 95% CI –4·37 to –0·41; p=0·02). 
When only the two studies10,28 at low risk of bias were 
included, SMD for weight gain was –0·21 (95% CI –0·61 
to 0·19; p=0·31), and SMD for length gain was 0·10 
(–0·21 to 0·42; p=0·52). One study, by Majumdar and 
colleagues,36 contributed eﬀ ect estimates for both 
change in weight and length that were substantially 
more negative than other studies; however, even when 
this study was excluded, we noted an adverse eﬀ ect 
from iron on weight gain (–0·32, –0·62 to –0·02; 
p=0·03); MD for length gain was –0·30 (–0·64 to 0·04; 
p=0·09).
Figure 3: Forest plots for eﬀ ects of daily iron supplementation on growth
(A) Final length. (B) Final length for age. (C) Length gain.
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 3·7%
 5·6%
 6·0%
 8·1%
 22·7%
 8·2%
 6·4%
 20·1%
 6·7%
 6·1%
 100·0%
22
140
94
78
161
163
197
54
187
153
56
152
185
1642
 –0·75 (0·84)
 –0·63 (1·09)
 –1·24 (0·87)
 –1·42 (0·85)
 –0·9 (0·9)
 –0·66 (0·91)
 –1·39 (0·84)
 –0·32 (0·25)
 –1·51 (0·79)
 –1 (0·8)
 –0·34 (0·25)
 –1 (0·7)
 –1·43 (0·92)
Idjradinata 199328
Domellof 200134
Dijkhuizen 200129
Dijkhuizen 200129
Lind 200323
Lind 200323
Berger 200632
Sazawal 200610
Berger 200632
Wasantwisut 200631
Sazawal 200610
Wasantwisut 200631
Fahmida 200735
Total
Heterogeneity τ2=0·00; χ2=12·45, df=12 (p=0·41); I2=4%
Test for overall eﬀect Z=0·37 (p=0·71) 
0–2–4 2 4
Favours control Favours iron
Favours control Favours iron
–0·5 –0·25 0 0·25 0·5
C
7
50
19
22
41
54
140
117
450
 1·34 (0·4)
 0·69 (0·06)
 3·08 (1·52)
 4 (1·41)
 0·48 (0·07)
 –0·32 (0·25)
 6·86 (0·39)
 4·5 (2·42)
 1·62 (0·83)
 0·97 (0·06)
 3·26 (1·54)
 3·9 (1·41)
 0·52 (0·07)
 –0·35 (0·26)
 7·27 (0·52)
 4·85 (1·71)
9
50
24
22
54
58
78
123
418
 10·7%
 11·6%
 12·4%
 12·4%
 13·0%
 13·1%
 13·3%
 13·4%
 100·0%
 –0·39 (–1·39 to 0·61)
 –4·96 (–5·77 to –4·16)
 –0·12 (–0·72 to 0·49)
 0·07 (–0·52 to 0·66)
 –0·57 (–0·98 to –0·15)
 0·12 (–0·25 to 0·49)
 –0·93 (–1·22 to –0·64)
 –0·17 (–0·42 to 0·09)
 –0·83 (–1·53 to –0·12)
Yalcin 200022
Mujumdar 200336
Nagpal 200430
Idjradinata 199328
Ziegler 200933
Sazawal 200610
Domellof 200134
Geltman 200137
Total
Heterogeneity τ2=0·96; χ2=149·21, df=7 (p<0·0001); I2=95%
Test for overall eﬀect Z=2·29 (p=0·02) 0 2 4–2–4
Favours control Favours iron
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Safety outcomes are summarised in the table. Iron 
supplementation increased the risk of vomiting; the eﬀ ect 
was still noted when only data from the one trial at low 
risk of bias was included: risk ratio 1·35 (95% CI 1·00–1·83; 
p=0·05). We identiﬁ ed no eﬀ ect from iron supplementation 
on constipation, or prevalence or incidence of diarrhoea, 
nor did iron aﬀ ect mortality (appendix pp 39–40). Children 
randomised to iron had an increased prevalence of fever. 
When only studies at low risk of bias (two trials) were 
included, the risk ratio was 0·99 (0·76–1·30; p=0·95). 
Iron supplementation did not aﬀ ect incidence of fever. 
There was no eﬀ ect from iron supplementation on 
incidence of lower respiratory infections. Berger and 
colleagues32 noted no evidence of an eﬀ ect from iron 
supplementation on prevalence of respiratory infections 
(risk ratio 1·05, 95% CI 0·92–1·20; p=0·45).
Malaria-related outcomes were reported in four 
studies.10,38–40 Meta-analysis showed that clinical malaria, 
A Mean diﬀerence
(95% CI)
Control
Mean (SD) Total
Experimental
Mean (SD) Total
 –0·37 (–1·05 to 0·31)
 0·00 (–0·27 to 0·27)
 0·30 (0·01 to 0·59)
 0·00 (–0·29 to 0·29)
 0·02 (–0·21 to 0·25)
 –0·08 (–0·31 to 0·15)
 –0·17 (–0·46 to 0·12)
 –0·14 (–0·32 to 0·04)
 0·10 (–0·10 to 0·30)
 –0·07 (–0·24 to 0·10)
 0·10 (–0·11 to 0·31)
 –0·32 (–0·66 to 0·02)
 –0·02 (–0·11 to 0·06)
 
22
98
90
80
143
134
24
191
151
195
153
54
1335
 10·13 (1·17)
 8 (0·9)
 7·8 (1)
 8·42 (1·09)
 8·31 (0·94)
 8·48 (0·97)
 6·51 (0·10)
 8·19 (0·92)
 8 (0·9)
 8·05 (0·8)
 8·1 (1)
 8·8 (0·83)
 1·4%
 7·4%
 6·5%
 6·5%
 9·3%
 9·4%
 6·4%
 12·6%
 11·1%
 14·0%
 10·3%
 5·0%
 100·0%
22
78
94
152
136
136
19
187
152
197
153
41
1367
 9·76 (1·13)
 8 (0·9)
 8·1 (1)
 8·42 (1·03) 
 8·33 (1·02)
 8·4 (0·94)
 6·34 (0·64)
 8·05 (0·9)
 8·1 (0·9)
 7·98 (0·9)
 8·2 (0·9)
 8·56 (0·84)
Idjradinata 199328
Dijkhuizen 200129
Dijkhuizen 200129
Domellof 200134
Lind 200323
Lind 200323
Nagpal 200430
Berger 200632
Wasantwisut 200631
Berger 200632
Wasantwisut 200631
Ziegler 200933
Total
Heterogeneity τ2=0·01; χ2=14·70, df=11 (p=0·20); I2=25%
Test for overall eﬀect Z=0·58 (p=0·56) 
B
 –0·14  (–0·67 to 0·39)
 0·18 (–0·09 to 0·45)
 –0·01 (–0·30 to 0·28)
 –0·06 (–0·32 to 0·20)
 –0·22 (–0·45 to 0·01)
 0·07 (–0·16 to 0·30)
 –0·06 (–0·25 to 0·13)
 –0·03 (–0·21 to 0·15)
 –0·17 (–0·34 to –0·00)
 –0·03 (–0·18 to 0·12)
 0·00 (–0·19 to 0·19)
 0·10 (–0·10 to 0·30)
 0·08 (–0·10 to 0·26)
 –0·02 (–0·08 to 0·03) 
22
90
78
98
162
164
44
58
191
195
151
153
189
1595
–0·97 (0·89)
–1·37 (0·91)
–0·46 (1·08)
–1·26 (0·85)
–1·46 (1·08)
–1·72 (1)
–0·22 (0·46)
–0·14 (0·44)
–1·54 (0·85)
–1·68 (0·75)
–1·3 (0·9)
–1·3 (0·9)
–1·71 (0·89)
 1·2%
 4·6%
 3·9%
 4·9%
 6·3%
 6·5%
 9·5%
 9·9%
 12·0%
 13·9%
 9·0%
 8·2%
 9·9%
 100·0%
22
94
140
78
161
163
56
54
187
197
152
153
185
1642
 –1·11 (0·89)
 –1·19 (0·95)
 –0·47 (1·01)
 –1·32 (0·89)
 –1·68 (1·02)
 –1·65 (1·08)
 –0·28 (0·49)
 –0·17 (0·54)
 –1·71 (0·8)
 –1·71 (0·81)
 –1·3 (0·8)
 –1·2 (0·9)
 –1·63 (0·92)
 
Idjradinata 199328
Dijkhuizen 200129
Domellof 200134
Dijkhuizen 200129
Lind 200323
Lind 200323
Sazawal 200610
Sazawal 200610
Berger 200632
Berger 200632
Wasantwisut 200631
Wasantwisut 200631
Fahmida 200735
Total
Heterogeneity τ2=0·00; χ2=11·82, df=12 (p=0·46); I2=x%
Test for overall eﬀect Z=0·79 (p=0·13) 
C
 –8·39 (–9·64 to 7·14)
 0·00 (–0·99 to 0·99)
 0·17 (–0·43 to 0·77)
 –0·49 (–1·09 to 0·11) 
 –1·09 (–1·53 to –0·66)
 –0·06 (–0·43 to 0·31)
 –0·44 (–0·72 to –0·16)
 –0·12 (–0·37 to 0·14)
 –1·12 (–1·01 to –0·33)
50
9
24
22
54
58
78
123
418
 0·25 (0·014)
 0·39 (0·11)
 0·703 (0·34)
 0·77 (0·52)
 13·61 (3·43)
 –0·14 (0·44)
 1800·69 (322·59)
 1·19 (0·77)
 10·2%
 11·3%
 12·6%
 12·7%
 13·1%
 13·3%
 13·4%
 13·5%
 100·0%
50
7
19
22
41
54
140
117
450
 0·14 (0·013)
 0·39 (0·12)
 0·778 (0·53)
 0·56 (0·28)
 10·09 (2·85)
 –0·17 (0·54)
 1667·29 (291·12)
 1·98 (1·1)
Mujumdar 200336
Yalcin 200022
Nagpal 200430
Idjradinata 199328
Ziegler 200933
Sazawal 200610
Domellof 200134
Geltman 200137
Total
Heterogeneity τ2=1·19; χ2=179·04, df=7 (p<0·0001); I2=96%
Test for overall eﬀect Z=2·78 (p=0·005) 
Weight
10·50–0·5–1
Favours control Favours iron
–0·5 –0·25 0 0·25 0·5
Favours control Favours iron
0–5–10 5 10
Favours control Favours iron
Figure 4: Forest plots for eﬀ ects of daily iron supplementation on growth
(A) Final weight. B) Final weight for age. (C) Weight gain. *Inverse variance, random eﬀ ects.
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parasitaemia, and parasite densities were not aﬀ ected by 
iron supplementation. Further descriptions of the 
ﬁ ndings of these trials are included in the appendix p 21.
Children randomised to iron had lower zinc 
concentrations than control children29,31,32,35,41,42 (MD –0·70 
(95% CI –1·37 to –0·03; p=0·04). When only the four 
trials32,31,35,42 at low risk of bias were included, MD was 
–0·80 (95% CI –1·65 to 0·04; p=0·06). Post-hoc 
subgroup analysis to compare the MD in trials 
comparing iron versus control, with the MD in trials 
comparing combined iron and zinc versus zinc alone, 
showed that children supplemented with iron and zinc 
in combination had reduced zinc concentrations 
compared with children receiving zinc alone (six 
studies, MD –1·77, 95% CI –3·01 to –0·52; p=0·005, 
I²=77%; ﬁ gure 5A), but children given iron alone did not 
have lower zinc concentrations compared with those 
receiving control (ﬁ ve studies, MD 0·12, –0·79 to 1·03; 
p=0·80, I²=85%), test for subgroup diﬀ erence p=0·01 
(ﬁ gure 5B).
Meta-analysis of adherence was not possible because 
of diﬀ erences in reporting between studies. Adherence 
was not reported in 11 studies. Another 11 studies 
showed no diﬀ erence in adherence between iron and 
control groups. Six studies administered all doses under 
supervision to ensure adherence. Two studies reported 
poorer adherence in children randomised to iron 
(appendix pp 18–20)  
Discussion
Our study shows that daily iron supplementation 
improves haemoglobin and iron indices and substantially 
reduces the risk of anaemia, iron deﬁ ciency, and 
especially IDA in children aged 4–23 months. However, 
beneﬁ ts to development and growth from daily iron 
supplementation in this age group are unclear. 
Participants of included studies were at high risk of 
anaemia (ie, 44% prevalence of anaemia at endpoint in 
the control group of the meta-analysis), iron deﬁ ciency 
(32% prevalence at endpoint in control group), and IDA 
(20% prevalence in control group). Most studies were 
done in low-income or middle-income settings. Our 
ﬁ ndings are thus relevant to anaemia control 
programmes in developing countries.
IDA is an important medical problem in young 
children (panel3,43–49), associated with symptoms including 
lethargy, irritability, pica, and poor oral intake. We 
identiﬁ ed a clear improvement in haemoglobin 
(MD 7·22 g/L, 26 studies) and reduction in the prevalence 
of anaemia (risk ratio 0·61, 17 studies; table) in children 
receiving daily iron supplementation. Gera and 
colleagues43 identiﬁ ed a similar eﬀ ect of iron on 
haemoglobin (MD 7·4 g/L) but did not do meta-analysis 
for anaemia, instead estimating that between 37·9% and 
62·3% of baseline anaemia is amenable to control by 
iron, less so in malaria-endemic areas. Likewise, we 
noted a smaller eﬀ ect from iron on anaemia in 
Figure 5: Forest plots for eﬀ ects of daily iron supplementation on zinc concentrations
(A) Iron plus zinc versus zinc alone. (B) Iron alone versus control, and overall. *Inverse variance, random eﬀ ects.
Favours control Favours iron
Favours control Favours iron
A
Mean diﬀerence
(95% CI)
Control
Mean (SD) Total
WeightExperimental
Mean (SD) Total
Fahmida 200735
Dijkhuizen 200129
Wieringa 200341
Wasantwisut 200631
Berger 200642
Lind 200342
Subtotal
Heterogeneity τ2=1·53; χ2=21·58, df=5 (p=0·0006); I2=77%
Test for overall eﬀect Z=2·78 (p=0·005)
 16.8 (7·7)
15 (9·32)
15.5 (3·9)
12.1 (3·8)
21·54 (5·19)
10·8 (1·34)
32
74
39
67
160
136
508
 18·4 (8·37)
 16·1 (7·02)
 16·5 (5·41)
 16·7 (5·2)
 23·07 (5·56)
 11·58 (1·41)
25
90
43
58
161
134
511
 2·1%
 4·6%
 6·2%
 7·8%
 10·0%
 13·9%
 44·7%
–1·60 (–5·83 to 2·63)
–1·10 (–3·67 to 1·47)
–1·00 (–3·03 to 1·03)
–4·60 (–6·22 to –2·98)
–1·53 (–2·71 to –0·35)
–0·78 (–1·11 to –0·45)
–1·77 (–3·01 to –0·52)
B
Dijkhuizen 200129
Wieringa 200341
Berger 200632
Wasantwisut 200631
Lind 200342
Subtotal
Heterogeneity τ2=0·83; χ2=25·95, df=4 (p<0·0001); I2=85%
Test for overall eﬀect Z=0·25 (p=0·80)
Total (A plus B)
Heterogeneity τ2=0·81; χ2=66·29, df=10 (p<0·0001); I2=85%
Test for overall eﬀect Z=2·06 (p=0·04)
Test for subgroup diﬀerences (A vs B) χ2=5·71, df=1 (p=0·02); I2=82·5%
 13·5 (5·27)
 13·5 (2·7)
 15·21 (3·65)
 11·5 (2·5)
 8·76 (1·24)
90
49
135
65
136
475
983
13 (6·21)
14·2 (2·96)
15·79 (3·81)
9·8 (1·9)
9·06 (1·27)
87
43
155
66
143
494
1005
 0·50 (–1·20 to 2·20)
 –0·70 (–1·86 to 0·46)
 –0·58 (–1·44 to 0·28)
 1·70 (0·94 to 2·46)
 –0·30 (–0·59 to –0·01)
 0·12 (–0·79 to 1·03)
 –0·70 (–1·37 to –0·03)
 7·5%
 10·0%
 11·6%
 12·1%
 14·0%
 55·3%
 100·0%
420–2–4
420–2–4
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malaria-endemic areas (risk ratio 0·70) than non-
endemic areas (0·40; appendix p 28). De-Regil and 
colleagues44 showed that multiple-micronutrient 
fortiﬁ cation reduced anaemia by 31% and iron deﬁ ciency 
by 51% in children younger than 2 years (six studies), 
whereas intermittent iron in children younger than 
12 years reduced anaemia by 49% and iron deﬁ ciency by 
76% (ten studies).12 We conclude that iron 
supplementation can be expected to halve the prevalence 
of anaemia in young children (with greater reductions in 
the prevalence of iron deﬁ ciency [risk ratio 0·30] and 
IDA [0·14]; table). These estimates should guide realistic 
targets for anaemia control programmes.
Previous systematic reviews have failed to identify 
evidence of beneﬁ t from iron on mental development in 
young children.45,50–52 Although we retrieved and included 
additional trials compared with previous reviews, we were 
also unable to ﬁ nd a beneﬁ cial overall eﬀ ect, perhaps 
attributable to several reasons. First, individual trials and 
the overall meta-analysis might be underpowered to ﬁ nd a 
signiﬁ cant diﬀ erence; a trial powered to identify a 1·6% 
improvement in Bayley’s mental development index (as 
recorded in our meta-analysis) would need about 
1300 children per group. Of 1093 children included in 
studies measuring Bayley’s mental development index, 
only 113 children known to be anaemic and 241 known to 
be iron deﬁ cient were recruited. Second, tests for cognitive 
development in children of this age used in included 
studies might be insensitive to small changes.53 Third, iron 
deﬁ ciency might cause an irreversible cognitive deﬁ cit in 
children that is refractory to iron supplementation. Finally, 
iron might not aﬀ ect cognitive development in children; 
however, this conclusion would be in contradiction with 
data from animal studies54 and beneﬁ ts from iron noted in 
children aged 2–5 years (preschool)55 and schoolchildren.45 
We did identify evidence with subgroup meta-analysis to 
suggest a beneﬁ cial eﬀ ect from iron in iron deﬁ cient 
children. This eﬀ ect was generated by the study by Akman 
and colleagues,20 which did not use a placebo in the control 
group and is therefore at high risk of bias, and the 
combined iron deﬁ ciency anaemia and non-anaemic iron 
deﬁ ciency subgroups of the study by Idjradinata and 
colleagues;28 of which only the iron deﬁ ciency anaemia 
subgroup showed evidence of beneﬁ t from iron. The 
inability to deﬁ nitively quantify cognitive beneﬁ ts from 
iron supplements aﬀ ects the risk–beneﬁ t analysis needed 
for appropriate guideline development.
Our ﬁ nding that daily iron supplementation impaired 
length gain and weight gain over the duration of follow-
up (even though we noted no diﬀ erences in ﬁ nal weight 
or length) raises concern. Changes from baseline scores 
are perhaps more valuable than comparison of ﬁ nal 
values, because they account for between-person baseline 
variability. Sachdev and colleagues46 likewise noted no 
evidence of beneﬁ t on growth in children receiving iron, 
and identiﬁ ed evidence to suggest impairment in linear 
growth in children receiving iron for longer than 
6 months or from developed countries. One potential 
mechanism for this ﬁ nding is that children given iron 
might have gastrointestinal symptoms (including 
vomiting as noted in our meta-analysis), impairing 
appetite and oral intake. The scarcity of data for the 
eﬀ ects of iron supplementation on growth in children 
who are anaemic or iron deﬁ cient limits the conclusions 
that can be drawn from these ﬁ ndings.
Although children receiving iron and zinc had lower 
zinc concentrations than children receiving zinc alone, 
these children still had higher absolute zinc concentrations 
(weighted mean 15·7 μmol/L) than children receiving 
iron alone (weighted mean 12·4 μmol/L) or control 
(12·4 μmol/L). Thus, coadministration of iron might 
impair eﬃ  cacy of zinc supplementation but does not 
seem to aﬀ ect de-novo zinc concentrations.
We did not identify evidence that daily oral iron 
supplementation increased malaria (although few studies 
were done in malaria-endemic areas or speciﬁ cally 
reported malaria-related outcomes), diarrhoea, or 
respiratory infection, but we did identify evidence that iron 
increased fever. A systematic review56 reported that iron 
did not increase the risk of clinical malaria, excluding sites 
where services did not provide for malaria surveillance and 
treatment, but did increase risk of parasitaemia. Taken 
together with our ﬁ nding that iron increased vomiting, 
these data reinforce the need for health worker monitoring 
of children receiving iron supplements.
We have improved on previous systematic reviews by 
using a more comprehensive search strategy, enabling us 
to include more studies than previous meta-analyses; by 
Panel: Research in context
We searched PubMed up to April 10, 2013, without language restriction, for systematic 
reviews assessing iron administration in children. We identiﬁ ed nine previous systematic 
reviews. A series of reviews assessed eﬀ ects of iron in children on haemoglobin (but not 
anaemia),43 cognitive and motor development,45 growth,46 exercise performance,47 and risk 
of infectious disease.48 These reviews combined age ranges of children and iron 
administration routes. Eﬀ ects of iron on development in non-anaemic iron-deﬁ cient 
children have also been reviewed,49 with authors ﬁ nding data inadequate to draw 
conclusions. The eﬀ ect of intermittent (1–3 times per week on non-consecutive days) iron13 
and multiple-micronutrient44 supplementation on nutritional and developmental 
outcomes in children has also been assessed, with few data for non-haematological 
outcomes. Finally, a review examined the eﬀ ects of daily iron supplementation in children 
aged 2–5 years.55 As far as we are aware, the eﬀ ects of daily iron supplementation have not 
been assessed by systematic review in children of this age group.
Interpretation
Daily iron improves haemoglobin and iron stores, and reduces the risk of anaemia, iron 
deﬁ ciency, and iron deﬁ ciency anaemia. However, only very few trials, recruiting relatively 
few children, have adequately studied non-haematological outcomes associated with 
iron supplementation in children with anaemia. There is inadequate evidence that iron 
improves cognitive development in this age group, although we noted a small beneﬁ t 
(non-statistically signiﬁ cant). High quality, suitably powered trials are needed to establish 
the risks and non-haematological beneﬁ ts from iron in this population. Health worker 
and parental monitoring of children receiving daily iron is advisable. 
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speciﬁ cally assessing daily iron supplementation, a 
widely recommended and implemented intervention 
strategy;57 and by comprehensively summarising the 
evidence for this intervention for a range of clinically 
important outcomes, in the age group in which anaemia 
control is deemed perhaps both most important3 and also 
most problematic. Our conclusions are limited by quality 
of included trials. Few studies reported methodology for 
randomisation and concealment of allocation, and only 
nine studies were considered at low risk of bias. It is 
possible that a larger number of studies had appropriately 
prevented bias but had not reported these methods. 
Reporting of adherence and supplement quality control 
was also suboptimum. There remains a paucity of high 
quality randomised controlled trials reporting non-
haematological outcomes.
Our systematic review was done in the context of 
growing uncertainty about the safety and optimum 
approach for iron supplementation to young children in 
low-income settings, prompted by data from high 
quality, adequately powered trials. Results of a 
randomised controlled trial9 of home-based iron-
containing multiple micronutrient fortiﬁ cation (not 
eligible for this review) showed that although 
micronutrients alleviated iron deﬁ ciency and anaemia, 
there was an increase in diarrhoea (including bloody 
diarrhoea) and respiratory illness in children randomised 
to intervention. Results of a randomised controlled trial58 
in Tanzanian children showed an increase in malarial 
episodes in iron-deﬁ cient children receiving 
micronutrients. A large randomised controlled trial10 
(included in this review) identiﬁ ed an increase in malaria 
and infection-related morbidity and mortality in 
Tanzanian children randomised to iron-folic acid.10 
Thus an urgent need exists to clarify the net beneﬁ ts and 
risks of iron supplementation to preschool children. Our 
ﬁ ndings conﬁ rm the beneﬁ t of iron supplementation for 
control of anaemia. However, beneﬁ ts on cognitive 
development and growth remain uncertain. Our data 
can inform the design of well-conducted, adequately 
powered trials that are still needed to deﬁ ne the beneﬁ ts 
and safety of iron supplementation in children of this 
age group.
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